Guanfacine Extended-Release for ADHD Treatment

Introduction to Guanfacine ER

Guanfacine ER offers the convenience of once-daily dosing, which can improve medication adherence compared to multiple daily doses required with IR formulations, according to the American Academy of Pediatrics 1, 2

Guanfacine works as an alpha-2A adrenergic receptor agonist, enhancing noradrenergic neurotransmission in the prefrontal cortex, which strengthens top-down regulation of attention, thought, and working memory, as stated by the American College of Neuropsychopharmacology 3, 4
Guanfacine ER is available in tablet form with doses of 1, 2, 3, and 4 mg, with dosing typically adjusted to body weight (approximately 0.1 mg/kg as a general guideline), as recommended by the American Academy of Pediatrics 1, 2

For preschool-aged children (4-6 years), methylphenidate is the recommended first-line pharmacologic treatment, as non-stimulant medications like guanfacine have not received sufficient rigorous study in this age group, according to the American Academy of Pediatrics 5
In countries where guanfacine ER is available, it is often positioned as a second-line treatment after stimulants have proven ineffective or not tolerated, as suggested by the European Society for Child and Adolescent Psychiatry 1, 2

In Japan, guanfacine extended-release (GXR) is available in 1 mg and 3 mg formulations with a maximum recommended daily dose of 6 mg, as stated by the Japanese Society of Child and Adolescent Psychiatry 6, 7, 8

The American Academy of Pediatrics recommends avoiding abrupt discontinuation of guanfacine ER; although studies suggest less rebound hypertension than with IR formulations, tapering is still recommended to minimize potential withdrawal effects 5
Guanfacine ER may take 2-4 weeks to show full therapeutic effects, unlike stimulants which typically work more rapidly, as noted by the American College of Neuropsychopharmacology 1, 2